Evidence map›Paper›PMID 32955798›Full record

ArticleCancer medicine2020

Sulfiredoxin-1 is a promising novel prognostic biomarker for hepatocellular carcinoma.

Qian-Wen Rao, Shi-Long Zhang, Meng-Zhou Guo, Fei-Fei Yuan, Jia-Lei Sun, Feng Qi, Li-Shun Wang, Bi-Wei Yang, Jing-Lin Xia

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Qian-Wen RaoMinhang Branch, Zhongshan Hospital, Fudan University, Shanghai, China.
Shi-Long ZhangInstitute of Fudan-Minhang Academic Health System, Minhang Branch, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID 0000-0003-3095-4246
Meng-Zhou GuoLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Fei-Fei YuanLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Jia-Lei SunLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Feng QiLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Li-Shun WangInstitute of Fudan-Minhang Academic Health System, Minhang Branch, Zhongshan Hospital, Fudan University, Shanghai, China.
Bi-Wei YangLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Jing-Lin XiaMinhang Branch, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID 0000-0003-1566-3934

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Identifying novel prognostic biomarkers for hepatocellular carcinoma (HCC) and then, develop an effective individualized treatment strategy remain extremely warranted. The prognostic role of sulfiredoxin-1(SRXN1), an antioxidant enzyme, remains unknown in HCC. This study aimed to explore the prognostic implications of SRXN1 in HCC patients after partial hepatectomy. The expression of SRXN1 in HCC and normal tissue were analyzed using the patients from the public databases and Zhongshan Hospital. The Cox regression, Kaplan-Meier survival analysis, and time-dependent receiver operating characteristic curves were performed to identify the predictive role of SRXN1 expression on HCC patients. A prognostic nomogram based on SRXN1 expression was constructed and validated to further confirm the predictive power of SRXN1 as a prognostic biomarker. Finally, functional enrichment analysis and protein-protein interaction network analysis of SRXN1 and its associated genes were conducted. The results showed that SRXN1 was upregulated in HCC samples compared with the normal liver tissues. Patients with SRXN1 upregulation had shorter survival time. SRXN1 overexpression was significantly correlated with advanced clinicopathological parameters. The prognostic nomogram based on SRXN1 expression was proved to be more accurate than routine staging systems for the prediction of overall survival. Protein-protein interaction network analysis demonstrated the first neighbor genes of SRXN1 mainly participated in response to oxidative stress. In brief, SRXN1 could be a prognostic biomarker for the management of HCC.

Indexed as

Biomarkers, TumorCarcinoma, HepatocellularDatabases, GeneticDecision Support TechniquesFemaleGene Expression RegulationGene Regulatory NetworksHepatectomyHumansLiver NeoplasmsMaleMiddle AgedNomogramsOxidoreductases Acting on Sulfur Group DonorsPredictive Value of TestsProtein Interaction MapsBiomarkers, TumorOxidoreductases Acting on Sulfur Group DonorsSRXN1 protein, humanHepatocellular carcinomanomogramprognosisSulfiredoxin-1survival analysis

Identifiers

PMID32955798
PMCPMC7666720

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.